Ryan Cohlhepp - 03 Mar 2026 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role: President and COO, Director
Signature: /s/ Lara Meisner, Attorney-in-Fact
Issuer symbol: BCAX
Transactions as of: 03 Mar 2026
Net transactions value: -$315,893
Form type: 4
Filing time: 05 Mar 2026, 19:10:29 UTC
Previous filing: 27 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cohlhepp Ryan	President and COO, Director	BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON	/s/ Lara Meisner, Attorney-in-Fact	05 Mar 2026	0002034665

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCAX	Common Stock	Options Exercise		+12,892	+6.1%	$3.79^*	222,533	03 Mar 2026	Direct	F1
transaction	BCAX	Common Stock	Sale	$234,159	-12,892	-5.8%	$18.16	209,641	03 Mar 2026	Direct	F1, F2
transaction	BCAX	Common Stock	Sale	$81,734	-4,500	-2.1%	$18.16	205,141	03 Mar 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCAX	Stock Option (Right to Buy)	Options Exercise		-12,892	-9.3%	$0.000000^*	125,334	03 Mar 2026	Common Stock	12,892	$3.79	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3	The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.